HIST1H2BK Predicts Neoadjuvant-chemotherapy Response and Mediates 5-fluorouracil Resistance of Gastric Cancer Cells

Overview

Journal Transl Oncol

Specialty Oncology

Date 2024 Jun 9

PMID 38852277

Authors

Zijian Chen

Xiaocheng Tang

Weiyao Li

Tuoyang Li

Jintuan Huang

Yingming Jiang

Jun Qiu

Zhenze Huang

Rongchang Tan

Xiang Ji

Li Lv

Zuli Yang

Hao Chen

Affiliations

Soon will be listed here.

Abstract

Background: Neoadjuvant chemotherapy (NACT) is routinely used to treat patients with advanced gastric cancer (AGC). However, the identification of reliable markers to determine which AGC patients would benefit from NACT remains challenging.

Methods: A systematic screening of plasma proteins between NACT-sensitive and NACT-resistant AGC patients was performed by a mass spectrometer (n = 6). The effect of the most differential plasma protein was validated in two independent cohorts with AGC patients undergoing NACT (ELISA cohort: n = 155; Validated cohort: n = 203). The expression of this candidate was examined in a cohort of AGC tissues using immunohistochemistry (n = 34). The mechanism of this candidate on 5-Fluorouracil (5-FU) resistance was explored by cell-biology experiments in vitro and vivo.

Results: A series of differential plasma proteins between NACT-sensitive and NACT-resistant AGC patients was identified. Among them, plasma HIST1H2BK was validated as a significant biomarker for predicting NACT response and prognosis. Moreover, HIST1H2BK was over-expression in NACT-resistant tissues compared to NACT-sensitive tissues in AGC. Mechanistically, HIST1H2BK inhibited 5-FU-induced apoptosis by upregulating A2M transcription and then activating LRP/PI3K/Akt pathway, thereby promoting 5-FU resistance in GC cells. Intriguingly, HIST1H2BK-overexpressing 5-FU-resistant GC cells propagated resistance to 5-FU-sensitive GC cells through the secretion of HIST1H2BK.

Conclusion: This study highlights significant differences in plasma protein profiles between NACT-resistant and NACT-sensitive AGC patients. Plasma HIST1H2BK emerged as an effective biomarker for achieving more accurate NACT in AGC. The mechanism of intracellular and secreted HIST1H2BK on 5-FU resistance provided a novel insight into chemoresistance in AGC.

References

Zhang S, Pan S, Lai S, Situ H, Liu J, Dai W . Novel Plasma Proteomic Biomarkers for Early Identification of Induction Chemotherapy Beneficiaries in Locoregionally Advanced Nasopharyngeal Carcinoma. Front Oncol. 2022; 12:889516. PMC: 9279567. DOI: 10.3389/fonc.2022.889516. View

Di Benedetto M, Toullec A, Buteau-Lozano H, Abdelkarim M, Vacher S, Velasco G . MDA-MB-231 breast cancer cells overexpressing single VEGF isoforms display distinct colonisation characteristics. Br J Cancer. 2015; 113(5):773-85. PMC: 4559830. DOI: 10.1038/bjc.2015.267. View

Mantuano E, Mukandala G, Li X, Campana W, Gonias S . Molecular dissection of the human alpha2-macroglobulin subunit reveals domains with antagonistic activities in cell signaling. J Biol Chem. 2008; 283(29):19904-11. PMC: 2459272. DOI: 10.1074/jbc.M801762200. View

Ychou M, Boige V, Pignon J, Conroy T, Bouche O, Lebreton G . Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011; 29(13):1715-21. DOI: 10.1200/JCO.2010.33.0597. View

Liu Y, Wang G, Zhang J, Chen X, Xu H, Heng G . CD9, a potential leukemia stem cell marker, regulates drug resistance and leukemia development in acute myeloid leukemia. Stem Cell Res Ther. 2021; 12(1):86. PMC: 7836575. DOI: 10.1186/s13287-021-02155-6. View

Nakamura Y, Kawazoe A, Lordick F, Janjigian Y, Shitara K . Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm. Nat Rev Clin Oncol. 2021; 18(8):473-487. DOI: 10.1038/s41571-021-00492-2. View

Lawrence M, Daujat S, Schneider R . Lateral Thinking: How Histone Modifications Regulate Gene Expression. Trends Genet. 2015; 32(1):42-56. DOI: 10.1016/j.tig.2015.10.007. View

Cunningham D, Allum W, Stenning S, Thompson J, van de Velde C, Nicolson M . Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006; 355(1):11-20. DOI: 10.1056/NEJMoa055531. View

Nurczyk K, Nowak N, Carlson R, Skoczylas T, Wallner G . Pre-therapeutic molecular biomarkers of pathological response to neoadjuvant chemotherapy in gastric and esophago-gastric junction adenocarcinoma: A systematic review and meta-analysis. Adv Med Sci. 2023; 68(1):138-146. DOI: 10.1016/j.advms.2023.02.005. View

10.

Carrasco-Garcia E, Garcia-Puga M, Arevalo S, Matheu A . Towards precision medicine: linking genetic and cellular heterogeneity in gastric cancer. Ther Adv Med Oncol. 2018; 10:1758835918794628. PMC: 6116075. DOI: 10.1177/1758835918794628. View

11.

Wang D, Zhao C, Xu F, Zhang A, Jin M, Zhang K . Cisplatin-resistant NSCLC cells induced by hypoxia transmit resistance to sensitive cells through exosomal PKM2. Theranostics. 2021; 11(6):2860-2875. PMC: 7806469. DOI: 10.7150/thno.51797. View

12.

Chen X, Leng W, Zhou Y, Yu Y, Meng W, Cao P . Pathological response and safety of FOLFOXIRI for neoadjuvant treatment of high-risk relapsed locally advanced colon cancer: study protocol for a single-arm, open-label phase II trial. BMJ Open. 2023; 13(1):e062659. PMC: 9890744. DOI: 10.1136/bmjopen-2022-062659. View

13.

Kang Y, Yook J, Park Y, Lee J, Kim Y, Kim J . PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer. J Clin Oncol. 2021; 39(26):2903-2913. PMC: 8425847. DOI: 10.1200/JCO.20.02914. View

14.

Singh R, Bassett E, Chakravarti A, Parthun M . Replication-dependent histone isoforms: a new source of complexity in chromatin structure and function. Nucleic Acids Res. 2018; 46(17):8665-8678. PMC: 6158624. DOI: 10.1093/nar/gky768. View

15.

Gray M, Mhawech-Fauceglia P, Yoo E, Yang W, Wu E, Lee A . AKT inhibition mitigates GRP78 (glucose-regulated protein) expression and contribution to chemoresistance in endometrial cancers. Int J Cancer. 2013; 133(1):21-30. PMC: 3633665. DOI: 10.1002/ijc.27994. View

16.

Terazawa T, Matsuyama J, Goto M, Kawabata R, Endo S, Imano M . A Phase II Study of Perioperative Capecitabine plus Oxaliplatin Therapy for Clinical SS/SE N1-3 M0 Gastric Cancer (OGSG 1601). Oncologist. 2020; 25(2):119-e208. PMC: 8696956. DOI: 10.1634/theoncologist.2019-0601. View

17.

Liu W, Xu Z, Zhou J, Xing S, Li Z, Gao X . High Levels of HIST1H2BK in Low-Grade Glioma Predicts Poor Prognosis: A Study Using CGGA and TCGA Data. Front Oncol. 2020; 10:627. PMC: 7225299. DOI: 10.3389/fonc.2020.00627. View

18.

Kim J, Ha Y, Park I, Kim C, Yoon Y, Lee J . Tumor immune microenvironment of primary colorectal adenocarcinomas metastasizing to the liver or lungs. J Surg Oncol. 2021; 124(7):1136-1145. DOI: 10.1002/jso.26631. View

19.

Guo N, Minas G, Synowsky S, Dunne M, Ahmed H, McShane R . Identification of plasma proteins associated with oesophageal cancer chemotherapeutic treatment outcomes using SWATH-MS. J Proteomics. 2022; 266:104684. DOI: 10.1016/j.jprot.2022.104684. View

20.

Kwee R, Kwee T . Role of imaging in predicting response to neoadjuvant chemotherapy in gastric cancer. World J Gastroenterol. 2014; 20(7):1650-6. PMC: 3930965. DOI: 10.3748/wjg.v20.i7.1650. View